Aura Biosciences, Inc. (AURA) has released encouraging early data from its ongoing Phase 1 trial of bel-sar (AU-011) for non-muscle-invasive bladder cancer (NMIBC). The data suggests bel-sar with light activation could be a promising new treatment option with rapid tumor response and potential for durable effects.